UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Combination strategies to maximize the benefits of cancer immunotherapy

Journal of hematology and oncology, 2021-09, Vol.14 (1), p.1-156, Article 156

2021

Volltextzugriff (PDF)

Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing

Journal of hematology and oncology, 2018-12, Vol.11 (1), p.142-142, Article 142

2018

Volltextzugriff (PDF)

Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy

Journal of hematology and oncology, 2020-04, Vol.13 (1), p.29-29, Article 29

2020

Volltextzugriff (PDF)

CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

Science (American Association for the Advancement of Science), 2011-03, Vol.331 (6024), p.1612-1616

2011

Volltextzugriff (PDF)

PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective

Journal of hematology and oncology, 2017-01, Vol.10 (1), p.34-34, Article 34

2017

Volltextzugriff (PDF)

Increasing cure rates of solid tumors by immune checkpoint inhibitors

Experimental hematology & oncology, 2023-01, Vol.12 (1), p.10-10, Article 10

2023

Volltextzugriff (PDF)

The role of biomarkers in personalized immunotherapy

Biomarker research, 2022-05, Vol.10 (1), p.32-32, Article 32

2022

Volltextzugriff (PDF)

Novel strategies for immuno-oncology breakthroughs with cell therapy

Biomarker research, 2021-07, Vol.9 (1), p.62-11, Article 62

2021

Volltextzugriff (PDF)

Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells

Cancer research (Chicago, Ill.), 2005-07, Vol.65 (13), p.5958-5964

2005

Volltextzugriff (PDF)

Systemic Antitumor Effect of Intratumoral Injection of Dendritic Cells in Combination with Local Photodynamic Therapy

Clinical cancer research, 2006-04, Vol.12 (8), p.2568-2574

2006

Volltextzugriff (PDF)

Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors

Cancer research (Chicago, Ill.), 2001-10, Vol.61 (20), p.7530-7535

2001

Volltextzugriff (PDF)

Proceedings of the 2016 China Cancer Immunotherapy Workshop

Journal of hematology and oncology, 2016-10, Vol.9 (1), p.1-8

2016

Volltextzugriff (PDF)

Marriage of Heterobuckybowls with Triptycene: Molecular Waterwheels for Separating C 60 and C 70

Chemistry : a European journal, 2022-04, Vol.28 (20), p.e202200306

2022

Volltextzugriff (PDF)

KP104, a Bifunctional C5 Antibody/Factor H Fusion Protein, Effectively Controls Both Intravascular and Extravascular Hemolysis: Interim Results from a Phase 2 Study in Complement Inhibitor-Naïve PNH Patients

Blood, 2023-11, Vol.142 (Supplement 1), p.572-572

2023

Volltextzugriff (PDF)

33 C5 cleavage inhibition combined with C3 convertase targeting protects from disease development in a preclinical model of autoimmune skin disease

Immunobiology (1979), 2023-09, Vol.228 (5), p.152487, Article 152487

2023

Volltextzugriff (PDF)

Opening two benzene rings on trichalcogenasumanenes toward high performance organic optical-limiting materials

Chemical communications (Cambridge, England), 2018, Vol.54 (78), p.10981-10984

2018

Volltextzugriff (PDF)

Marriage of Heterobuckybowls with Triptycene: Molecular Waterwheels for Separating C60 and C70

Chemistry : a European journal, 2022-04, Vol.28 (20), p.e202200306-n/a

2022

Volltextzugriff (PDF)

221 SYNERGY-1: A Phase 1, first-in-human, randomized, double-blind, placebo-controlled safety, tolerability, immunogenicity, PK and PD study of KP104 in escalating single and multiple doses

Immunobiology (1979), 2023-09, Vol.228 (5), p.152671, Article 152671

2023

Volltextzugriff (PDF)

Trial in Progress: An Open-Label, Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104 in Complement Inhibitor-Naïve Subjects with Paroxysmal Nocturnal Hemoglobinuria

Blood, 2022-11, Vol.140 (Supplement 1), p.11459-11460

2022

Volltextzugriff (PDF)

SYNERGY-1: A Phase 1, First-in-Human, Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics Study of KP104 in Escalating Single and Multiple Doses: SA-PO636

Journal of the American Society of Nephrology, 2022-11, Vol.33 (11S), p.779-779

2022

Volltextzugriff (PDF)

Opening two benzene rings on trichalcogenasumanenes toward high performance organic optical-limiting materialsElectronic supplementary information (ESI) available: Synthetic details, characterization of the compounds, theoretical calculations, and additional optical spectra. See DOI: 10.1039/c8cc05480k

2018-09

Volltextzugriff (PDF)

Novel technologies and emerging biomarkers for personalized cancer immunotherapy

Journal for Immunotherapy of Cancer, 2016-01, Vol.4 (1), p.3, Article 3

2016

Volltextzugriff (PDF)

Lymphoma Immunotherapy with CpG Oligodeoxynucleotides Requires TLR9 Either in the Host or in the Tumor Itself

Journal of Immunology, 2007-08, Vol.179 (4), p.2493-2500

2007

Volltextzugriff (PDF)

Immune monitoring technology primer: whole exome sequencing for neoantigen discovery and precision oncology

Journal for immunotherapy of cancer, 2016-04, Vol.4 (22), Article 22

2016

Volltextzugriff (PDF)

1 – 25 von 112

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(104)
Mit Volltextzugriff
(105)

Publikationsform

Artikel
(111)
Dissertationen
(1)

Sprache

Englisch
(108)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Combination strategies to maximize the benefits of cancer immunotherapy

Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing

Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy

CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective

Increasing cure rates of solid tumors by immune checkpoint inhibitors

The role of biomarkers in personalized immunotherapy

Novel strategies for immuno-oncology breakthroughs with cell therapy

Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells

Systemic Antitumor Effect of Intratumoral Injection of Dendritic Cells in Combination with Local Photodynamic Therapy

Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors

Proceedings of the 2016 China Cancer Immunotherapy Workshop

Marriage of Heterobuckybowls with Triptycene: Molecular Waterwheels for Separating C 60 and C 70

KP104, a Bifunctional C5 Antibody/Factor H Fusion Protein, Effectively Controls Both Intravascular and Extravascular Hemolysis: Interim Results from a Phase 2 Study in Complement Inhibitor-Naïve PNH Patients

33 C5 cleavage inhibition combined with C3 convertase targeting protects from disease development in a preclinical model of autoimmune skin disease

Opening two benzene rings on trichalcogenasumanenes toward high performance organic optical-limiting materials

Marriage of Heterobuckybowls with Triptycene: Molecular Waterwheels for Separating C60 and C70

221 SYNERGY-1: A Phase 1, first-in-human, randomized, double-blind, placebo-controlled safety, tolerability, immunogenicity, PK and PD study of KP104 in escalating single and multiple doses

Trial in Progress: An Open-Label, Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104 in Complement Inhibitor-Naïve Subjects with Paroxysmal Nocturnal Hemoglobinuria

SYNERGY-1: A Phase 1, First-in-Human, Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics Study of KP104 in Escalating Single and Multiple Doses: SA-PO636

Novel technologies and emerging biomarkers for personalized cancer immunotherapy

Lymphoma Immunotherapy with CpG Oligodeoxynucleotides Requires TLR9 Either in the Host or in the Tumor Itself

Immune monitoring technology primer: whole exome sequencing for neoantigen discovery and precision oncology

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers

Suchergebnisse filtern